BSWH Transplant Annual Report 2016 ACHC_639_2017_AnnualReport_JO_PROOF8 | Page 27

ISLET TRANSPLANT 2016 ISLET CELL TRANSPLANT RESEARCH HIGHLIGHTS Identification of novel anti- inflammatory small molecules to improve islet cell transplantation outcomes. The Baylor Dallas team identified Withaferin A, a small molecule extracted from the plant Withania Somnifera as a promising compound. Identification and validation of biomarkers for islet damage. The Baylor Dallas team identified microRNA-375 as a sensitive and specific marker for islet cell damage using in vitro and in vivo studies. continued to be one of the top five programs in the country. The Liver and Pancreas Disease Center at Baylor Dallas brings all of the necessary resources together to manage the pre- and post- surgery care of islet cell transplant patients. With a statewide and national reputation for industry-leading care, the Baylor Dallas islet cell transplant program receives referrals from a wide geographic area. A support group of islet cell transplant patients also meets regularly at Baylor Dallas. In addition, Baylor Scott & White –  Fort Worth sponsors a Liver and Pancreas Disease center that provided outpatient evaluation and disease management of approximately 120 patients in 2016. Also in 2016, the center offered a unique service called the quality of life phone survey. It was conducted with patients to determine the degree to which their disease was impacting their lives. Analysis of cell signaling pathways critical for islet cell survival. The Baylor Dallas team analyzed the role of NFAT, a transcription factor, in mediating islet cell inflammation. ISLET CELLS 25